Skip to main content
OpenTrials
Completed

NCT Number: NCT01789060

p-AKT Expression on Clinical Outcomes in Malignant Lymphoma

PI3K(phosphatidylinositol 3-kinase)/AKT pathway is an important oncogenic signaling pathway. However, clinical information about the significance of p-AKT expression in malignant lymphoma is not fully understood yet. In this study, we investigated the overexpression of p-AKT and its prognostic implication in malignant lymphoma.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Malignant Lymphoma Hemic and Lymphatic Diseases Immune System Diseases Immunoproliferative Disorders Lymphatic Diseases Lymphoma Lymphoproliferative Disorders Neoplasms Neoplasms by Histologic Type P13K-AKT Pathway Deregulation

Age range

17 year–90 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Samsung Medical Center

Seoul, South Korea

About this study

Recently, among diverse oncogenic signaling pathways, a number of studies have focused on the significance of oncogenic PI3K/AKT (phophatidylinositol 3-kinase/serine-threonine kinase, also known as protein kinase B [PKB]) pathway. PI3K(phosphatidylinositol 3-kinase)/AKT pathway phosphorylates and activates AKT as phosphorylated AKT (p-AKT) and plays a critical role promoting malignant phenotype and has prognostic significance in various solid cancers.

However, a systematic approach on the impact of p-AKT overexpression on clinical outcomes has not been performed in malignant lymphoma.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • the patients were pathologically confirmed of malignant lymphoma, according to the World Health Organization classification;
  • the patients had adequate paraffin-embedded biopsy specimen or unstained slides for immunostaining of p-AKT.

Exclusion criteria

  • Primary central nervous system lymphoma was excluded in this study

Treatment and study plan

p-AKT immunohistochemical staining

Other

p-AKT staining on the adequate paraffin-embedded biopsy specimen or unstained slides

Primary outcomes

  1. Difference of overall survival according to p-AKT status in malignant lymphoma

    Time frame: study entry

Secondary outcomes

  1. Subgroup analysis of overall survival according to histologic subtypes (GCB vs non GCB)

    Time frame: study entry

Other outcomes

  1. Subgroup analysis of overall survival according to International Prognostic Index risk groups

    Time frame: study entry

Sponsors and collaborators

Lead sponsor

Samsung Medical Center

Other

Registry information

Official study title

The Impact of Activated p-AKT Expression on Clinical Outcomes in Malignant Lymphoma : A Clinicopathological Study

Important dates

Study start
2012
Primary completion
2013
Study completion
2013
First posted
Feb 11, 2013
Registry last updated
Feb 11, 2013

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.